Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL
Author
Hodder, AngusMishra, Avijeet K
Enshaei, Amir
Baird, Susan
Elbeshlawi, Ismail
Bonney, Denise
Clesham, Katherine
Cummins, Michelle
Vedi, Aditi
Gibson, Brenda
George, Lindsay
Ingham, Danielle
Jigoulina, Galina
Lancaster, Donna
Lindsay, Katherine
Madni, Majid
Malone, Andrea
Mitchell, Bethany
Moppett, John
Motwani, Jayashree
Moorman, Anthony V
Patrick, Katharine
Samrin, Lamia
Tewari, Sanjay
Thakur, Indu
O'Connor, David
Samarasinghe, Sujith
Vora, Ajay
Publication date
2023-11-15Subject
Oncology. Pathology.
Metadata
Show full item recordAbstract
From February 2018 to February 2023, 105 patients were treated, of whom 85 were in the Blin-CT group and 20 were in the Blin-HSCT group. A majority of Blin-CT patients received Blina for chemotherapy intolerance (70 of 85, 82%), and the group had a higher-risk profile than unselected patients with B-ALL. Blina was well tolerated with only one patient having a grade 3/4-related toxicity event, and of the 60 patients who were minimal residual disease-positive pre-Blina, 58 of 60 (97%) responded. At a median follow-up of 22 months, the 2-year outcomes of the 80 matched Blin-CT group patients were similar to those of 192 controls (EFS, 95% [95% CI, 85 to 98] v 90% [95% CI, 65 to 93] and OS, 97% [95% CI, 86 to 99] v 94% [95% CI, 89 to 96]). Of the 20 in the HSCT group, three died because of transplant complications and two relapsed.Citation
Hodder A, Mishra AK, Enshaei A, Baird S, Elbeshlawi I, Bonney D, Clesham K, Cummins M, Vedi A, Gibson B, George L, Ingham D, Jigoulina G, Lancaster D, Lindsay K, Madni M, Malone A, Mitchell B, Moppett J, Motwani J, Moorman AV, Patrick K, Samrin L, Tewari S, Thakur I, O'Connor D, Samarasinghe S, Vora A. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL. J Clin Oncol. 2024 Mar 10;42(8):907-914. doi: 10.1200/JCO.23.01392. Epub 2023 Nov 15.Type
ArticlePMID
37967307Journal
Journal of Clinical OncologyPublisher
American Society of Clinical Oncologyae974a485f413a2113503eed53cd6c53
10.1200/JCO.23.01392